摘要
目的检测HBV相关慢加急性肝衰竭(ACLF)患者血清M30、M65的水平,探讨其与疾病的关系。方法选取31例HBV相关ACLF患者(好转20例,无效11例);20例慢性乙型肝炎(CHB)患者,10例健康人为对照,采用ELISA方法检测外周血清中M30、M65水平,多组间数据比较采用方差分析,两两比较采用q检验。结果 ACLF组血清M30[(508.65±340.16)U/L]、M65[(768.75±290.02)U/L]高于CHB组[(212.27±91.33)U/L,P<0.05;(384.40±134.46)U/L,P<0.05]和健康对照组[(94.12±17.64)U/L,P<0.05;(121.99±29.25)U/L,P<0.05]。ACLF患者血清M30与M65水平呈正相关(r=0.78,P<0.05)。好转组与无效组血清M30、M65水平差异无统计学意义[(572.38±349.45)vs(436.14±285.59)U/L,P=0.29;(817.25±307.66)vs(703.90±221.37)U/L,P=0.31]。结论 M30、M65水平能够较为准确的反映肝脏的细胞凋亡及坏死程度,在HBV相关ACLF患者中显著升高。
ObjectiveTo determine the serum M30 and M65 levels in patients with HBV-related acute-on-chronic liver failure (ACLF) and to investigate their association with this disease. MethodsThirty-one patients with HBV-related ACLF (20 cases with response to treatment and 11 cases without response to treatment), 20 patients with chronic hepatitis B (CHB), and 10 healthy controls were enrolled in the study. Serum M65 and M30 levels were measured by enzyme-linked immunosorbent assay. Analysis of variance was used for comparison among groups; q-test was used for pairwise comparison. ResultsThe serum M30 and M65 levels of ACLF patients (508.65±340.16 and 768.75±290.02 U/L) were significantly higher than those of CHB patients (212.27±91.33 and 384.40±134.46 U/L) and healthy controls (94.12±17.64 and 121.99±29.25 U/L) (P〈0.05 for all comparisons). In the ACLF patients, the serum level of M30 was positively correlated with that of M65 (r=0.78, P〈0.05); no significant differences were seen between the cases with response to treatment and those without response to treatment in serum M30 and M65 levels (572.38±349.45 vs 436.14±285.59 U/L, P=0.29; 81725±307.66 vs 703.90±221.37 U/L, P=0.31). ConclusionSerum levels of M30 and M65 are sensitive indicators for the necrosis and apoptosis of hepatocytes. Significant increases in serum M30 and M65 levels are observed in patients with HBV-related ACLF.
出处
《临床肝胆病杂志》
CAS
2013年第9期678-680,共3页
Journal of Clinical Hepatology
基金
解放军302医院院内课题资助项目(YNKT2012002)